Senti Biosciences (NasdaqCM:SNTI) Update / Briefing December 09, 2025 08:00 AM ET Company ParticipantsKanya Rajangam - President, Head of R&D and Chief Medical OfficerNosha Farhadfar - Hematologist and Bone Marrow Transplant PhysicianTimothy Lu - CEO and Co-founderConference Call ParticipantsYale Jen - Senior Managing Director and Senior Biotech AnalystNone - AnalystGeulah Livshits - Senior Research AnalystOperatorHello, and welcome to the Senti Biosciences Senti 202 Clinical Update Conference Call and Webc ...

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced it will host a conference call and webcast to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting on Tuesday, December 9, 2025 at 8:00 AM ET. The call will be hosted by Timothy Lu, MD, PhD, Chief Executive ...